Utilization of Healthcare Resources in Osteoarthritis: A Cost of Illness Analysis Based on Real-World Data in Italy

Giorgio Lorenzo Colombo,1 Franca Heiman,2 Ilaria Peduto2 1CEFAT - Department of Drug Sciences, University of Pavia, Pavia, Italy; 2Real World Solutions, IQVIA Solutions Italy S.r.l., Milan, ItalyCorrespondence: Ilaria PedutoIQVIA Solutions Italy S.r.l., Via Fabio Filzi 29, Milan, 20124, ItalyEmail i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Colombo GL, Heiman F, Peduto I
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	osteoarthritis costs real-world italy Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/a11ab4ab8dd84787b5d1ccbd41153368
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a11ab4ab8dd84787b5d1ccbd41153368
record_format	dspace
spelling	oai:doaj.org-article:a11ab4ab8dd84787b5d1ccbd411533682021-12-02T16:41:24ZUtilization of Healthcare Resources in Osteoarthritis: A Cost of Illness Analysis Based on Real-World Data in Italy1178-203Xhttps://doaj.org/article/a11ab4ab8dd84787b5d1ccbd411533682021-04-01T00:00:00Zhttps://www.dovepress.com/utilization-of-healthcare-resources-in-osteoarthritis-a-cost-of-illnes-peer-reviewed-fulltext-article-TCRMhttps://doaj.org/toc/1178-203XGiorgio Lorenzo Colombo,1 Franca Heiman,2 Ilaria Peduto2 1CEFAT - Department of Drug Sciences, University of Pavia, Pavia, Italy; 2Real World Solutions, IQVIA Solutions Italy S.r.l., Milan, ItalyCorrespondence: Ilaria PedutoIQVIA Solutions Italy S.r.l., Via Fabio Filzi 29, Milan, 20124, ItalyEmail ilaria.peduto@iqvia.comPurpose: Understand the demographics and clinical features of patients with osteoarthritis (OA), quantify healthcare resource utilization by OA patients, and estimate the annual direct medical costs per OA patient from a National Health Service (NHS) perspective in Italy.Patients and Methods: Retrospective observational cohort analysis using data from electronic medical records captured by the Italian IQVIA Longitudinal Patient Database (LPD). Only direct medical costs reimbursed by the NHS were considered. Patients were included if they received at least one diagnosis of OA during the period from January 1 to December 31, 2018. Each patient was observed for 3 years: a 24-month baseline period preceding the index date, and a 12-month follow-up period starting at the index date.Results: A total of 71,467 patients met inclusion criteria: 43.98% had not been prescribed NSAIDs/opioids, 40.76% had been prescribed NSAIDs, and 15.26% an opioid. Mean age was 71.36 years, and 68.2% of the patients were women. At least one comorbidity was present in 91.34% of the patients; 38.05% were newly diagnosed with OA. During 1-year of follow-up, 173,884 prescriptions with an associated diagnosis of OA were found: 47.36% had been prescribed an NSAID, 9.11% diclofenac, 8.30% codeine+paracetamol, and 7.32% ketoprofen. Nearly 15% of the patients had at least 1 request for a specialist visit and 23.82% had at least 1 request for exams. Orthopedic visits accounted for 60% of all specialist visits. Yearly mean costs per patient were € 622, for approximately € 2.5 billion per year in direct costs, considering 3.9 million patients with OA in Italy. Protheses were a major driver in annual costs: € 143.45 in patients without a prosthesis and € 10,090.91 in those with a joint prosthesis.Conclusion: This real-world analysis of direct costs of care of patients with OA in Italy confirms the substantial economic burden. Direct costs dramatically increased when joint replacement was needed.Keywords: osteoarthritis, costs, real-world, ItalyColombo GLHeiman FPeduto IDove Medical Pressarticleosteoarthritiscostsreal-worlditalyTherapeutics. PharmacologyRM1-950ENTherapeutics and Clinical Risk Management, Vol Volume 17, Pp 345-356 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	osteoarthritis costs real-world italy Therapeutics. Pharmacology RM1-950
spellingShingle	osteoarthritis costs real-world italy Therapeutics. Pharmacology RM1-950 Colombo GL Heiman F Peduto I Utilization of Healthcare Resources in Osteoarthritis: A Cost of Illness Analysis Based on Real-World Data in Italy
description	Giorgio Lorenzo Colombo,1 Franca Heiman,2 Ilaria Peduto2 1CEFAT - Department of Drug Sciences, University of Pavia, Pavia, Italy; 2Real World Solutions, IQVIA Solutions Italy S.r.l., Milan, ItalyCorrespondence: Ilaria PedutoIQVIA Solutions Italy S.r.l., Via Fabio Filzi 29, Milan, 20124, ItalyEmail ilaria.peduto@iqvia.comPurpose: Understand the demographics and clinical features of patients with osteoarthritis (OA), quantify healthcare resource utilization by OA patients, and estimate the annual direct medical costs per OA patient from a National Health Service (NHS) perspective in Italy.Patients and Methods: Retrospective observational cohort analysis using data from electronic medical records captured by the Italian IQVIA Longitudinal Patient Database (LPD). Only direct medical costs reimbursed by the NHS were considered. Patients were included if they received at least one diagnosis of OA during the period from January 1 to December 31, 2018. Each patient was observed for 3 years: a 24-month baseline period preceding the index date, and a 12-month follow-up period starting at the index date.Results: A total of 71,467 patients met inclusion criteria: 43.98% had not been prescribed NSAIDs/opioids, 40.76% had been prescribed NSAIDs, and 15.26% an opioid. Mean age was 71.36 years, and 68.2% of the patients were women. At least one comorbidity was present in 91.34% of the patients; 38.05% were newly diagnosed with OA. During 1-year of follow-up, 173,884 prescriptions with an associated diagnosis of OA were found: 47.36% had been prescribed an NSAID, 9.11% diclofenac, 8.30% codeine+paracetamol, and 7.32% ketoprofen. Nearly 15% of the patients had at least 1 request for a specialist visit and 23.82% had at least 1 request for exams. Orthopedic visits accounted for 60% of all specialist visits. Yearly mean costs per patient were € 622, for approximately € 2.5 billion per year in direct costs, considering 3.9 million patients with OA in Italy. Protheses were a major driver in annual costs: € 143.45 in patients without a prosthesis and € 10,090.91 in those with a joint prosthesis.Conclusion: This real-world analysis of direct costs of care of patients with OA in Italy confirms the substantial economic burden. Direct costs dramatically increased when joint replacement was needed.Keywords: osteoarthritis, costs, real-world, Italy
format	article
author	Colombo GL Heiman F Peduto I
author_facet	Colombo GL Heiman F Peduto I
author_sort	Colombo GL
title	Utilization of Healthcare Resources in Osteoarthritis: A Cost of Illness Analysis Based on Real-World Data in Italy
title_short	Utilization of Healthcare Resources in Osteoarthritis: A Cost of Illness Analysis Based on Real-World Data in Italy
title_full	Utilization of Healthcare Resources in Osteoarthritis: A Cost of Illness Analysis Based on Real-World Data in Italy
title_fullStr	Utilization of Healthcare Resources in Osteoarthritis: A Cost of Illness Analysis Based on Real-World Data in Italy
title_full_unstemmed	Utilization of Healthcare Resources in Osteoarthritis: A Cost of Illness Analysis Based on Real-World Data in Italy
title_sort	utilization of healthcare resources in osteoarthritis: a cost of illness analysis based on real-world data in italy
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/a11ab4ab8dd84787b5d1ccbd41153368
work_keys_str_mv	AT colombogl utilizationofhealthcareresourcesinosteoarthritisacostofillnessanalysisbasedonrealworlddatainitaly AT heimanf utilizationofhealthcareresourcesinosteoarthritisacostofillnessanalysisbasedonrealworlddatainitaly AT pedutoi utilizationofhealthcareresourcesinosteoarthritisacostofillnessanalysisbasedonrealworlddatainitaly
_version_	1718383589348868096

Utilization of Healthcare Resources in Osteoarthritis: A Cost of Illness Analysis Based on Real-World Data in Italy

Ejemplares similares